RU2012101995A - Фармацевтический агент - Google Patents

Фармацевтический агент Download PDF

Info

Publication number
RU2012101995A
RU2012101995A RU2012101995/15A RU2012101995A RU2012101995A RU 2012101995 A RU2012101995 A RU 2012101995A RU 2012101995/15 A RU2012101995/15 A RU 2012101995/15A RU 2012101995 A RU2012101995 A RU 2012101995A RU 2012101995 A RU2012101995 A RU 2012101995A
Authority
RU
Russia
Prior art keywords
spp
pharmaceutical agent
agent according
cytokine
inflammation
Prior art date
Application number
RU2012101995/15A
Other languages
English (en)
Russian (ru)
Inventor
Грегори СТОЛОФФ
Уилсон ВАНДЕРЛЕЙ
Original Assignee
Пептселл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0910754A external-priority patent/GB0910754D0/en
Priority claimed from GB0913956A external-priority patent/GB0913956D0/en
Priority claimed from GB0920790A external-priority patent/GB0920790D0/en
Application filed by Пептселл Лимитед filed Critical Пептселл Лимитед
Publication of RU2012101995A publication Critical patent/RU2012101995A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012101995/15A 2009-06-22 2010-06-22 Фармацевтический агент RU2012101995A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0910754.1 2009-06-22
GB0910754A GB0910754D0 (en) 2009-06-22 2009-06-22 Pharmaceutical agent
GB0913956.9 2009-08-10
GB0913956A GB0913956D0 (en) 2009-08-10 2009-08-10 Pharmaceutical agent
GB0920790.3 2009-11-27
GB0920790A GB0920790D0 (en) 2009-11-27 2009-11-27 Pharmaceutical agent
PCT/EP2010/058788 WO2010149641A2 (en) 2009-06-22 2010-06-22 Pharmaceutical agent

Publications (1)

Publication Number Publication Date
RU2012101995A true RU2012101995A (ru) 2013-07-27

Family

ID=42727542

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012101995/15A RU2012101995A (ru) 2009-06-22 2010-06-22 Фармацевтический агент

Country Status (10)

Country Link
US (1) US20120100155A1 (https=)
EP (1) EP2424893A2 (https=)
JP (1) JP2012530755A (https=)
KR (1) KR20120044937A (https=)
CN (1) CN102459339A (https=)
AU (1) AU2010264764A1 (https=)
BR (1) BRPI1013525A2 (https=)
CA (1) CA2764257A1 (https=)
RU (1) RU2012101995A (https=)
WO (1) WO2010149641A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142387A1 (en) * 2012-03-19 2013-09-26 Cardiomems, Inc. Pulmonary arterial hemodynamic monitoring for chronic obstructive pulmonary disease assessment and treatment
WO2013179302A1 (en) 2012-05-15 2013-12-05 Rajesh Shah Oral anti-inflammatory formulation comprising potentised cytokine
EP2922465A4 (en) 2012-11-21 2016-07-06 Cardiomems Inc DEVICES, SYSTEMS AND METHODS FOR ASSESSING AND TREATING PULMONARY ARTERIAL HYPERTENSION (PAH)
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN111214495B (zh) * 2020-03-02 2021-12-31 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462454B2 (en) * 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
RU2332236C1 (ru) * 2007-02-02 2008-08-27 Олег Ильич Эпштейн Лекарственное средство для лечения гриппа у птиц
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy

Also Published As

Publication number Publication date
WO2010149641A2 (en) 2010-12-29
KR20120044937A (ko) 2012-05-08
AU2010264764A1 (en) 2011-12-08
EP2424893A2 (en) 2012-03-07
JP2012530755A (ja) 2012-12-06
WO2010149641A3 (en) 2011-02-24
CA2764257A1 (en) 2010-12-29
US20120100155A1 (en) 2012-04-26
BRPI1013525A2 (pt) 2016-04-05
CN102459339A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
RU2012101995A (ru) Фармацевтический агент
Barnes Cytokine modulators as novel therapies for airway disease
JP2012530755A5 (https=)
Van Reeth Cytokines in the pathogenesis of influenza
JP2018009002A5 (https=)
JP2017080507A5 (https=)
Dias et al. Adamalysins in COVID-19–Potential mechanisms behind exacerbating the disease
WO2020231855A4 (en) Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
Xu et al. Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: an open prospective cohort study
CN115484964A (zh) 冠状病毒感染和相关细胞因子毒性的治疗
Abou Baker Can natural products modulate cytokine storm in SARS-CoV2 patients?
Nadimi Parashkouhi et al. The dual sides of interferon induction in COVID-19 treatment
Akbulut et al. Effect of COVID-19 pandemic on patients who have undergone liver transplantation because of hepatocellular carcinoma
JP2023526536A5 (https=)
Ritchie et al. Viral infection
Kim et al. Respiratory Protective Effect of a RML on PM10D-induced Lung Injury Mouse Model
Varghese et al. Therapeutic plasma exchange using convalescent plasma replacement therapy in severe COVID-19 infections: a potential therapeutic option
Pekcan et al. Successful Therapy with intravenous gamma globulin in two children with postinfectious bronchiolitis obliterans
CN111228480A (zh) 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
谷憲治 et al. A case of sarcoidosis associated with chronic eosinophilic pneumonia
Jackson et al. Effects of GHRH-R Antagonist MIA-602 or Agonist MR-409 on Human iAT2 Cells Exposed to Cytokines or LPS
CN101057840A (zh) Vam3在制备治疗慢性阻塞性肺疾病的药物中的应用
CN105412112A (zh) Roquefortine F在制备治疗慢性阻塞性肺疾病药物中的应用
Cottin Idiopathic eosinophilic pneumonias
Bartlett et al. IL-25 Inhibits Airway Anti-Viral Immunity and Promotes Virus Exacerbation of Allergic Airways Disease